- Home
- FIEE vs KZR Comparison
FIEE vs KZR Comparison
Compare FIEE & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FIEE | KZR |
|---|---|---|
| Founded | 1977 | 2015 |
| Country | Hong Kong | United States |
| Employees | 43 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.6M | 54.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | FIEE | KZR |
|---|---|---|
| Price | $6.50 | $7.29 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 7.1K | ★ 88.5K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $3.53 |
| 52 Week High | $7.95 | $7.55 |
Technical Indicators
Market Signals| Indicator | FIEE | KZR |
|---|---|---|
| Relative Strength Index (RSI) | 36.91 | 54.64 |
| Support Level | $5.70 | $7.25 |
| Resistance Level | $7.28 | $7.47 |
| Average True Range (ATR) | 0.33 | 0.11 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 18.31 | 37.50 |
Price Performance
Historical ComparisonAbout FIEE FiEE Inc
FiEE Inc, formerly Minim Inc is a digital service provider focused on integrating artificial intelligence and data analytics into content creation and brand management. The company offers a range of services designed to support creators, artists, and businesses in developing, managing, and optimizing their digital presence across various platforms, including customized graphic and posts, short videos, and editorial calendars aligned with brand goals.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.